With the advent of small-molecule immune modulators, recombinant fusion proteins, and monoclonal antibodies, treatment options for patients with rheumatic diseases are now broad. These agents carry significant risks and an individualized approach to each patient, balancing known risks and benefits, remains the most prudent course. This review summarizes the available immunosuppressant treatments, discusses their perioperative implications, and provides recommendations for their perioperative management.
Keywords: Biologic therapy; Medication therapy management; Perioperative period; Rheumatic diseases.
Copyright © 2023 Elsevier Inc. All rights reserved.